Biomarker detection firm appoints new chairman

Biomarker detection company Compandia has appointed Dr Dave Tapolczay – CEO of Medical Research Council Technology – as its new non executive chairman. The Nottingham Trent University spin-out company employs state-of-the-art technology and university expertise in improving the success rate and lowering the cost of pharmaceutical manufacturer’s human drug trials.

Chief Executive Officer of Compandia, Andy Sutton, said: “We’re thrilled to have Dave join us as chairman. He brings with him years of experience and expertise from a CV that includes jobs with the largest pharmaceutical manufacturers in the world. His wealth of knowledge in the trends and activities of the biotechnology sector has us well placed for the optimal delivery of our services.”

Alongside Dave’s appointment as chairman, Compandia is also celebrating the launch of its new ‘Pathway’s Distiller’ – a tool that will allow the company’s scientists to provide unique insight into genetic pathways critical for pharmaceutical manufacturers developing combination therapies.

www.compandia.co.uk